Bolt Biotherapeutics (BOLT) Accumulated Expenses (2020 - 2026)
Bolt Biotherapeutics (BOLT) posted Accumulated Expenses of $896000.0 for Q1 2026, down 45.43% sequentially from $1.6 million in Q4 2025, and down 86.31% YoY from $6.5 million in Q1 2025.
Bolt Biotherapeutics (BOLT) Accumulated Expenses (2020 - 2026) Analysis & Trends
Bolt Biotherapeutics has reported Accumulated Expenses for 7 years, with the latest figure at $896000.0 in Q1 2026.
- Quarterly Accumulated Expenses fell 86.31% year-over-year to $896000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $896000.0 (down 86.31% YoY) and the FY2025 annual result came in at $1.6 million, down 56.34% from the prior year.
- Accumulated Expenses fell to $896000.0 in Q1 2026 per BOLT's latest filing, from $1.6 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $15.1 million in Q4 2022 and troughed at $896000.0 in Q1 2026.
- A 5-year average of $6.7 million and a median of $6.1 million in 2023 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2024 and 2025: Accumulated Expenses soared 313.54% in 2024, then slumped 87.11% in 2025.
- Over 5 years, Accumulated Expenses stood at $15.1 million in 2022, then tumbled by 59.76% to $6.1 million in 2023, then plunged by 38.26% to $3.8 million in 2024, then tumbled by 56.34% to $1.6 million in 2025, then sank by 45.43% to $896000.0 in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $896000.0, $1.6 million, and $1.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Bolt Biotherapeutics | 6.10 Mn | 6.10 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.09 Mn |
| Mar 31, 2026 | 896,000.00 |
| Dec 31, 2025 | 1.64 Mn |
| Sep 30, 2025 | 1.52 Mn |
| Jun 30, 2025 | 3.30 Mn |
| Mar 31, 2025 | 6.55 Mn |
| Dec 31, 2024 | 3.76 Mn |
| Sep 30, 2024 | 11.81 Mn |
| Jun 30, 2024 | 4.02 Mn |
| Mar 31, 2024 | 9.71 Mn |
| Dec 31, 2023 | 6.09 Mn |
| Sep 30, 2023 | 10.45 Mn |
| Jun 30, 2023 | 9.92 Mn |
| Mar 31, 2023 | 2.35 Mn |
| Dec 31, 2022 | 15.14 Mn |
| Sep 30, 2022 | 14.79 Mn |
| Jun 30, 2022 | 3.03 Mn |
| Mar 31, 2022 | 9.35 Mn |
| Dec 31, 2021 | 4.89 Mn |
| Sep 30, 2021 | 10.92 Mn |